The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., OLSSON, A. G., Carlsson, B., Klein, I. L., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
Merkel, M., Loeffler, B., Kluger, M. A., Fabig, N., Geppert, G., Pennacchio, L. A., Laatsch, A., & Heeren, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411412200 · Cited by 292
Phillips, A. N., & Smith, G. D. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90155-3 · Cited by 275
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255
El Harchaoui, K., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.043 · Cited by 239
Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
Packard, C. J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311066 · Cited by 225
Maio, A., & Dowd, F. J. (2008) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60628-2 · Cited by 207
The paradox of dysfunctional high-density lipoprotein
Ansell, B. J., Fonarow, G. C., & Fogelman, A. M. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282364a17 · Cited by 198
Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization
Smith, G. D., Timpson, N. J., & Ebrahim, S. B. J. (2008) · Annals of Medicine · doi:10.1080/07853890802010709 · Cited by 112
Nilsson, S. K., Christensen, S., Raarup, M. K., Ryan, R. O., Nielsen, M. S., & Olivecrona, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802721200 · Cited by 111
Thompson, S. G., Kaptoge, S., White, I. R., Wood, A., Perry, P., & Danesh, J. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq063 · Cited by 110
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
Gaddi, A. V., Cicero, A. F. G., Odoo, F. O., Poli, A. A., & Paoletti, R. (2007) · PubMed Central · Cited by 92
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
Preiss, D., & Sattar, N. A. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03490.x · Cited by 80
New approaches to target microsomal triglyceride transfer protein
Hussain, M. M., & Bakillah, A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328312707c · Cited by 78
Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia
Barter, P. J., & Ginsberg, H. N. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.056 · Cited by 73
Fibrinogen Studies Collaboration (2009) · Statistics in Medicine · doi:10.1002/sim.3530 · Cited by 63
Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation
Mauldin, K., & Ryan, R. O. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328133856c · Cited by 44
Matsuda, D., & Tomoda, H. (2007) · PubMed · Cited by 41
Palmen, J., Smith, A. J. P., Dorfmeister, B., Putt, W., Humphries, S. E., & Talmud, P. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.03.003 · Cited by 40
Impact of Apolipoprotein A5 Variants on Statin Treatment Efficacy
Hubacek, J. A., Adámková, V., Prusíková, M., Šnejdrlová, M., Hirschfeldová, K., Lánská, V., Češka, R., & Vrablı́k, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.17 · Cited by 39
Avian apolipoprotein A-V binds to LDL receptor gene family members
Dichlberger, A., Cogburn, L. A., Nimpf, J., & Schneider, W. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.c600026-jlr200 · Cited by 33
Cardona, F., Guardiola, M., Queipo‐Ortuño, M. I., Murri, M., Ribalta, J., & Tinahones, F. J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.024 · Cited by 26
Microsomal triglyceride transfer protein inhibition–friend or foe?
JOY, T. R., & Hegele, R. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1251 · Cited by 18
Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?
Sarwar, N., & Sattar, N. A. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd4dc · Cited by 18
Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates
Hegele, R. A., & Pollex, R. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.144980 · Cited by 11
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
